폐렴 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 감염 유형별, 유형별, 약제클래스별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)
Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Infection Type, By Type, By Drug Class, By End User, By Region and Competition, 2020-2030F
상품코드:1886319
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 폐렴 치료제 시장은 2024년 29억 1,000만 달러에서 2030년까지 45억 6,000만 달러로, CAGR 7.76%로 성장할 것으로 예측됩니다. 폐렴 치료제는 폐포의 염증을 특징으로 하는 심각한 호흡기 감염인 폐렴과 싸우는 것을 목표로 하는 의약품 개입 및 의료 절차의 일종입니다. 세계 시장의 확대는 주로 호흡기 질환의 세계 발생률이 지속적으로 증가하고 있으며, 특히 노인과 유아 등 감수성이 높은 계층에서 두드러지게 나타나고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
29억 1,000만 달러
시장 규모 : 2030년
45억 6,000만 달러
CAGR : 2025-2030년
7.76%
가장 빠르게 성장하는 부문
지역사회획득 폐렴(CAP)
최대 시장
북미
주요 시장 성장 촉진요인
세계 폐렴 치료제 시장은 전 세계 폐렴 발생률 증가와 항생제 내성 위협 증가로 인해 크게 견인되고 있습니다. 전 세계에서 폐렴 발생률이 지속적으로 높은 수준으로 유지되고 있으며, 초기 항균제 치료부터 지지요법까지 다양한 치료적 개입이 필요한 환자 수가 지속적으로 증가하고 있습니다.
주요 시장 과제
새로운 광범위 항생제 및 항바이러스 치료제에 대한 막대한 자금 투자와 엄격한 규제 승인 절차는 세계 폐렴 치료제 시장의 성장에 큰 장벽으로 작용하고 있습니다. 초기 연구부터 시장 진입까지의 길고 복잡한 여정은 막대한 자본을 필요로 하며, 잠재적인 혁신가들의 발목을 잡고 제약회사들이 이 중요한 분야에 대한 투자 의욕을 떨어뜨릴 수 있습니다.
주요 시장 동향
모노클로널 항체 및 숙주 지향적 치료와 같은 새로운 치료군의 출현은 세계 폐렴 치료제 시장에서 중요한 성장 추세를 보이고 있습니다. 이러한 혁신적인 치료법은 기존의 항생제를 넘어 감염과 싸우고 항균제 내성 문제를 해결할 수 있는 새로운 메커니즘을 제공합니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 폐렴 치료제 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
감염 유형별(원내 폐렴[HAP], 지역사회획득 폐렴[CAP], 인공호흡기 관련 폐렴[VAP])
유형별(약제, 예방 백신, 산소 요법)
약제클래스별(항균제, 항바이러스제, 항진균제)
최종사용자별(병원·진료소, 외래 수술 센터, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 폐렴 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 폐렴 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 폐렴 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 폐렴 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 폐렴 치료제 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병·인수
제품 출시
최근 동향
제13장 세계의 폐렴 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Pfizer Inc.
AstraZeneca Plc.
Eli Lilly & company
F. Hoffmann-La Roche Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Sanofi SA
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Limited
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Pneumonia Therapeutics Market will grow from USD 2.91 Billion in 2024 to USD 4.56 Billion by 2030 at a 7.76% CAGR. Pneumonia therapeutics comprise a class of pharmaceutical interventions and medical treatments aimed at combating pneumonia, a serious respiratory infection characterized by inflammation of the lung's air sacs. The global market's expansion is fundamentally propelled by the persistent high global incidence of respiratory illnesses, particularly among susceptible demographics such as the elderly and young children.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.91 Billion
Market Size 2030
USD 4.56 Billion
CAGR 2025-2030
7.76%
Fastest Growing Segment
Community-Acquired Pneumonia [CAP]
Largest Market
North America
Key Market Drivers
The global pneumonia therapeutics market is significantly driven by the increasing worldwide incidence of pneumonia and the escalating threat of antibiotic resistance. The persistent high global incidence of pneumonia creates a continuous and expanding patient population requiring various therapeutic interventions, from initial antimicrobial treatments to supportive care. This rising burden necessitates robust market supply and fosters demand for improved treatment efficacy and accessibility across diverse demographics.
Key Market Challenges
The substantial financial investment and stringent regulatory approval processes for new broad-spectrum antibiotics and antiviral treatments pose a significant impediment to the growth of the global pneumonia therapeutics market. The lengthy and complex journey from initial research to market entry demands considerable capital, which can deter potential innovators and reduce the incentive for pharmaceutical companies to invest in this critical area. This is particularly relevant for novel agents, where the inherent risk of failure is high, and the return on investment can be uncertain due to evolving pathogen resistance and specific treatment protocols aimed at preserving drug efficacy.
Key Market Trends
The emergence of novel therapeutic classes, such as monoclonal antibodies and host-directed therapies, represents a significant growth trend in the global pneumonia therapeutics market. These innovative treatments move beyond traditional antibiotics, offering new mechanisms to combat infection and address the pressing challenge of antimicrobial resistance. Monoclonal antibodies provide targeted immune responses, while host-directed therapies modulate the body's own defense mechanisms, potentially leading to broader efficacy and reduced development of resistance.
Key Market Players
Pfizer Inc.
AstraZeneca Plc.
Eli Lilly & company
F. Hoffmann-La Roche Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Sanofi SA
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Limited
Report Scope:
In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Pneumonia Therapeutics Market, By Infection Type:
Hospital-acquired Pneumonia [HAP]
Community-acquired Pneumonia [CAP]
Ventilator-associated Pneumonia [VAP]
Pneumonia Therapeutics Market, By Type:
Drugs
Preventive Vaccines
Oxygen Therapy
Pneumonia Therapeutics Market, By Drug Class:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Pneumonia Therapeutics Market, By End User:
Hospitals and Clinics
Ambulatory Surgical Centers
Others
Pneumonia Therapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Pneumonia Therapeutics Market.
Available Customizations:
Global Pneumonia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pneumonia Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])
5.2.2. By Type (Drugs, Preventive Vaccines, Oxygen Therapy)
5.2.3. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)
5.2.4. By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Pneumonia Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Infection Type
6.2.2. By Type
6.2.3. By Drug Class
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Pneumonia Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Infection Type
6.3.1.2.2. By Type
6.3.1.2.3. By Drug Class
6.3.1.2.4. By End User
6.3.2. Canada Pneumonia Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Infection Type
6.3.2.2.2. By Type
6.3.2.2.3. By Drug Class
6.3.2.2.4. By End User
6.3.3. Mexico Pneumonia Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Infection Type
6.3.3.2.2. By Type
6.3.3.2.3. By Drug Class
6.3.3.2.4. By End User
7. Europe Pneumonia Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Infection Type
7.2.2. By Type
7.2.3. By Drug Class
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pneumonia Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Infection Type
7.3.1.2.2. By Type
7.3.1.2.3. By Drug Class
7.3.1.2.4. By End User
7.3.2. France Pneumonia Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Infection Type
7.3.2.2.2. By Type
7.3.2.2.3. By Drug Class
7.3.2.2.4. By End User
7.3.3. United Kingdom Pneumonia Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Infection Type
7.3.3.2.2. By Type
7.3.3.2.3. By Drug Class
7.3.3.2.4. By End User
7.3.4. Italy Pneumonia Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Infection Type
7.3.4.2.2. By Type
7.3.4.2.3. By Drug Class
7.3.4.2.4. By End User
7.3.5. Spain Pneumonia Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Infection Type
7.3.5.2.2. By Type
7.3.5.2.3. By Drug Class
7.3.5.2.4. By End User
8. Asia Pacific Pneumonia Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Infection Type
8.2.2. By Type
8.2.3. By Drug Class
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pneumonia Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Infection Type
8.3.1.2.2. By Type
8.3.1.2.3. By Drug Class
8.3.1.2.4. By End User
8.3.2. India Pneumonia Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Infection Type
8.3.2.2.2. By Type
8.3.2.2.3. By Drug Class
8.3.2.2.4. By End User
8.3.3. Japan Pneumonia Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Infection Type
8.3.3.2.2. By Type
8.3.3.2.3. By Drug Class
8.3.3.2.4. By End User
8.3.4. South Korea Pneumonia Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Infection Type
8.3.4.2.2. By Type
8.3.4.2.3. By Drug Class
8.3.4.2.4. By End User
8.3.5. Australia Pneumonia Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Infection Type
8.3.5.2.2. By Type
8.3.5.2.3. By Drug Class
8.3.5.2.4. By End User
9. Middle East & Africa Pneumonia Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Infection Type
9.2.2. By Type
9.2.3. By Drug Class
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pneumonia Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Infection Type
9.3.1.2.2. By Type
9.3.1.2.3. By Drug Class
9.3.1.2.4. By End User
9.3.2. UAE Pneumonia Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Infection Type
9.3.2.2.2. By Type
9.3.2.2.3. By Drug Class
9.3.2.2.4. By End User
9.3.3. South Africa Pneumonia Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Infection Type
9.3.3.2.2. By Type
9.3.3.2.3. By Drug Class
9.3.3.2.4. By End User
10. South America Pneumonia Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Infection Type
10.2.2. By Type
10.2.3. By Drug Class
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pneumonia Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Infection Type
10.3.1.2.2. By Type
10.3.1.2.3. By Drug Class
10.3.1.2.4. By End User
10.3.2. Colombia Pneumonia Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Infection Type
10.3.2.2.2. By Type
10.3.2.2.3. By Drug Class
10.3.2.2.4. By End User
10.3.3. Argentina Pneumonia Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Infection Type
10.3.3.2.2. By Type
10.3.3.2.3. By Drug Class
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Pneumonia Therapeutics Market: SWOT Analysis
